9 results
In a fMRI experiment, will measure the changes in brain activity patterns and in functional connectivity. We hypothesize that a subanesthetic dose of S-Ketamine impairs the functional connectivity, especially the feedback connections that are…
This study is intended to establish a dose response rate of MR30507/09 with respect to respiratory effects compared to MR30365/07, fentanyl and placebo..
By means of resting state network measurments using fMRI we hope to gain more knowlegde about the actions (for example as an analgesic) an side effects of S(+)-ketamine on the central nervous system at different doses. Also blood samples will be…
The objectives are to assess the pharmacokinetic and pharmacodynamic effects of sub-anesthetic ketamine administration, to assess the optimal dose of ketamine and gender differences, to compare different oucome measures for psychomimetic symptoms…
1. Measure DNIC and offset analgesia in CRPS-1 patients, fibromyalgia patients and neuropathic pain patients;2. Compare DNIC and offset analgesia in chronic pain patients with DNIC and offset analgesia in healthy volunteers;3. Assess the effect of…
The purpose of this study is to find out how safe and effective a new drug called bimekizumab is for long-term use in treating hidradenitis suppurativa. Bimekizumab (hereafter referred to as *the study drug*) has been approved by the health…
Objective(s): Primary objective:The primary objective is to demonstrate the efficacy of bimekizumab administered subcutaneously every 4 weeks (sc Q4W) compared to placebo in the treatment of subjects with active nr-axSpA.Secondary objectives:The…
Primary Objective:The primary objective of this study is to compare the efficacy of bimekizumab administered scfor 16 weeks versus secukinumab at achieving complete clearance (PASI100) in subjects withmoderate to severe chronic plaque PSO.The…
Objective(s): Primary objective:The primary objective is to demonstrate the efficacy of bimekizumab administered subcutaneously (sc) every 4 weeks (Q4W) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).…